NORITATE (metronidazole) by Bausch + Lomb. Approved for nitroimidazole antimicrobial [epc]. First approved in 1997.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
NORITATE is a topical cream formulation of metronidazole, a nitroimidazole antimicrobial agent approved in 1997 for dermatologic infections. It is applied directly to affected skin areas and works by disrupting microbial DNA synthesis. The product is indicated for conditions caused by susceptible anaerobic bacteria and protozoa.
Low-revenue, mature product with minimal Part D penetration; commercial team likely focused on retention and cost management rather than growth initiatives.
Nitroimidazole Antimicrobial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Worked on NORITATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNORITATE presents limited career growth opportunities due to its LOE-approaching status, minimal clinical activity, and low revenue footprint ($3M Part D spending in 2023). Roles linked to this product are primarily defensive—focused on market retention, generic transition, and customer retention rather than expansion.